Clinical Trials Logo

Clinical Trial Summary

A first-in-human study using NJH395 in non-breast HER2-positive advanced malignancies


Clinical Trial Description

This study has two parts. There will be a single dose of NJH395 in the first part and multiple doses of NJH395 in the second part. After the first part is completed, the second part may open. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03696771
Study type Interventional
Source Novartis
Contact
Status Completed
Phase Phase 1
Start date December 27, 2018
Completion date October 19, 2020